Synairgen & Omega Diagnostics: 2 AIM pharma stocks for a healthy portfolio

2 min read | September 09, 2021 05:34 PM AEST | By Nidhi Gupta

Synairgen & Omega Diagnostics: 2 AIM pharma stocks for a healthy portfolio — Image source: Hparatlala, Shutterstock.com

Omega Diagnostics Group Plc (LON:ODX)

Omega Diagnostics Group is a medical diagnostics firm that primarily focuses on the areas of CD4 markers, infectious diseases, and food sensitivity testing. Recently, the company filed for CE-mark on Covid-19 antigen self-test ‘Visitect’.

For the year ended 31 March 2021, Omega Diagnostics Group recorded an 11% year-on-year decline in revenue to £8.73 million (2020: £9.82 million). It recorded a cash balance of £5.8 million as of 31 March 2021 (2020: overdraft of £0.6 million). The company’s EBITDA loss for the year ended 31 March 2021 stood at £2.20 million compared to £0.89 million EBITDA profit in 2020.

The shares of Omega Diagnostics traded at GBX 53.50 at the close of trade on 8 September 2021, and the market capitalisation stood at £97.71 million.

Synairgen Plc (LON:SNG)

Synairgen is a drug discovery and biotechnology company. The company is engaged in the development of inhaled interferon beta (IFN-beta) treatment for viral respiratory diseases, including COVID-19.

Synairgen’s cash balance as of 31 December 2021 stood at £75.0 million compared to £2.5 million as of 31 December 2019. In October 2020, the company generated £87.1 million to fund the SG018 Phase III trial. It recorded an operating loss of £17.7 million for the year ended 31 December 2020 (2019: £4.8 million), which includes R&D expenditure amounting to £15.5 million (2019: £3.5 million).

The shares of Synairgen last traded at GBX 150.20 on 8 September 2021, and the market capitalisation stood at £310.07 million.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.